<DOC>
	<DOC>NCT00271817</DOC>
	<brief_summary>To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.</brief_summary>
	<brief_title>To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient with LDLC of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL Patient willing to be on a lowcholesterol diet Pregnant or lactating women or intending to become pregnant Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin Patient for whom discontinuation of existing lipidlowering therapy treatment poses an unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>